Approval was based on findings from the phase 3 VERITAC-2 trial showing significantly improved PFS for patients with ESR1-mutated disease.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/vepdegestrant-earns-fda-nod-esr1-mutated-breast-cancer-2026a1000e23?src=rss
Author :
Publish date : 2026-05-01 20:14:00
Copyright for syndicated content belongs to the linked Source.